The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component ...
Zimmer Biomet Holdings, Inc. ZBH is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting ...
Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTion™ Femur, a ...
The device company generated revenues of $7.7bn in 2024, up 3.8% from 2023. Zimmer Biomet offers a range of orthopaedic implants and robotic technologies for joint replacement. Areas of the body ...
The Smart Orthopedic Implants market is expected to grow from an estimated USD 26.21 Billion in 2024 to USD 40.66 Billion in ...
March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings ... clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with ...
March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings ... clearance of Persona ® Revision SoluTionTM Femur, a revision knee implant component offering an alternative for patients with ...
A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...